Literature DB >> 2723436

Functional role of human IgG subclasses in eosinophil-mediated killing of schistosomula of Schistosoma mansoni.

J Khalife1, D W Dunne, B A Richardson, G Mazza, K J Thorne, A Capron, A E Butterworth.   

Abstract

Although IgG antibodies and eosinophils have been shown to kill schistosomula of Schistosoma mansoni in vitro, very little data exist that describe the role of each IgG antibody isotype in this event. This study was designed to test the role of each IgG subclass in the eosinophil-dependent killing reaction. IgG antibodies purified by protein G or protein A affinity chromatography demonstrated a killing effect only in the presence of eosinophils activated in vivo or normal eosinophils activated in vitro by eosinophil activating factor. Purification of each IgG isotype allowed confirmation of these results and demonstrated that the killing effect was associated with IgG1 and IgG3 antibodies. IgG2 antibodies expressed a dual function: 1) an effector function with activated eosinophils and 2) a blocking function with normal eosinophils. IgG4 antibodies, whatever the source of eosinophils, blocked the killing mediated by IgG effector antibodies. These findings are discussed in relation to immunity and susceptibility to reinfection in human schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723436

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity.

Authors:  H Bouharoun-Tayoun; P Druilhe
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 3.  Schistosome vaccines.

Authors:  D W Taylor
Journal:  Experientia       Date:  1991-02-15

4.  Specificity of IgG subclass antibodies in different clinical manifestations of leprosy.

Authors:  S Dhandayuthapani; S Izumi; D Anandan; V N Bhatia
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Human immunoglobulin E responses to a recombinant 22.6-kilodalton antigen from Schistosoma mansoni adult worms are associated with low intensities of reinfection after treatment.

Authors:  M Webster; A J Fulford; G Braun; J H Ouma; H C Kariuki; J C Havercroft; K Gachuhi; R F Sturrock; A E Butterworth; D W Dunne
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

6.  Human onchocerciasis and tetanus vaccination: impact on the postvaccination antitetanus antibody response.

Authors:  P J Cooper; I Espinel; M Wieseman; W Paredes; M Espinel; R H Guderian; T B Nutman
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Blocking anti-Trichinella spiralis antibodies in chronically infected rats.

Authors:  S M Venturiello; S N Costantino; G H Giambartolomei
Journal:  Parasitol Res       Date:  1996       Impact factor: 2.289

8.  Immunoglobulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4.

Authors:  Mario Jiz; Jennifer F Friedman; Tjalling Leenstra; Blanca Jarilla; Archie Pablo; Gretchen Langdon; Sunthorn Pond-Tor; Hai-Wei Wu; Daria Manalo; Remigio Olveda; Luz Acosta; Jonathan D Kurtis
Journal:  Infect Immun       Date:  2009-03-09       Impact factor: 3.441

9.  Isotypic analysis of Plasmodium falciparum-specific antibodies and their relation to protection in Madagascar.

Authors:  B Dubois; P Deloron; P Astagneau; C Chougnet; J P Lepers
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Characterisation of the protective immune response following subcutaneous vaccination of susceptible mice against Trichuris muris.

Authors:  Helen Dixon; Matthew C Little; Kathryn J Else
Journal:  Int J Parasitol       Date:  2009-12-05       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.